nasopharyngeal carcinoma
Conditions
Interventions
Experimental group:None
Control group:none
Sponsors
Guangdong Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age range: 18-70 years old 2. Meet the diagnostic criteria for recurrent nasopharyngeal malignant tumor disease: 3. No treatment was taken before the enrollment of this episode 4. It belongs to the T3 and T4 stages 5. No other life-threatening diseases 6. KPS>=70, can tolerate surgery and chemotherapy 7. Patients voluntarily participate in this study, and sign a written informed consent form, and are willing to cooperate with follow-up
Exclusion criteria
Exclusion criteria: 1. T stage T1, T2, or metastatic disease (M1); 2. The first treatment is not controlled; 3. Patients with a history of concurrent or multiple tumors; 4. At the time of screening examination, the patient's alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is greater than or equal to 1.5 times of the upper limit of normal specified by the center, or the endogenous creatinine clearance rate (CCr) is greater than the upper limit of normal specified by the center; 5. The total number of white blood cells (WBC) in the patient's blood routine at the screening examination is greater than 10.0X10^9/L or less than 1.0X10^9/L; 6. The patient has a history of immunodeficiency diseases (such as HIV, etc.), or a history of cancer, malignant tumors, or autoimmune diseases, or serious cardiovascular and cerebrovascular diseases, or other diseases that may significantly reduce life expectancy; 7. Have a history of any disease that may affect protocol compliance (such as severe mental disorder, cognitive dysfunction, substance abuse or addiction, etc.); 8. Pregnant or lactating women, or those of childbearing potential who are unwilling/unable to take effective contraceptive measures; 9. Those who are known to be allergic to the ingredients contained in the drug in this study; 10. Those who have participated in any drug clinical trials within 6 months before the screening examination; 11. Patients judged by the investigator to be unsuitable to participate in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tumor volume;survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| biochemical indicators; | — |
Countries
China
Contacts
Public ContactQianHui Qiu
Guangdong Provincial People's Hospital
Outcome results
None listed